HeartSciences Inc. announced its financial results for the first quarter of fiscal 2026, showcasing substantial progress and key achievements.
The Company launched MyoVista Insights, a cloud-native software platform designed to modernize legacy ECG management systems and facilitate AI-ECG algorithms.
CPT reimbursement codes are now in place for AI-ECG through MyoVista Insights, providing cost-efficient and seamless adoption for healthcare providers.
MyoVista Insights Launch
Successfully developed and launched a cloud-native software platform for AI-ECG algorithms, with no need for healthcare providers to purchase new ECG devices.
CPT Reimbursement Codes
Approval of reimbursement codes by CMS (Medicare) supports AI-ECG adoption, benefiting hospitals, insurers, physicians, and patients.
Future Goals
Anticipated phased rollout of the platform, alongside the launch of cloud-based algorithm for detecting reduced ejection fraction, to revolutionize the ECG management software market.
- The FDA Breakthrough Device Designation for HeartSciences' aortic stenosis ECG algorithm enhances the Company's credibility and potential market position.
- Investments in MyoVista Insights and the MyoVista wavECG device signal a strategic focus on innovation and capturing a share of the multibillion-dollar ECG software market.
HeartSciences' achievements in the first quarter of fiscal 2026 demonstrate a strong regulatory strategy and commitment to revolutionizing ECG technology. The Company's progress in AI-ECG adoption and product development positions it for significant growth in the healthcare industry.